Rajkumar Kannan
Vorstandsvorsitzender bei I-MAB
Profil
Rajkumar Kannan currently works at I-MAB Biopharma Co., Ltd., as Chief Executive Officer & Director, I-Mab, as Chief Executive Officer & Director from 2023, and Amryt Pharma Plc, as Non-Executive Director from 2021.
Mr. Kannan also formerly worked at Aerie Pharmaceuticals, Inc., as Chief Executive Officer & Director from 2021 to 2022, Chiasma, Inc., as President, Chief Executive Officer & Director in 2021, Amryt Pharma Holdings Ltd., as Non-Executive Director, Merck KGaA, as Global Head-Neurology & Immunology from 1995 to 2004, Boehringer Ingelheim Corp., as Head-Cardiovascular Franchise Global Marketing from 2004 to 2014, and Kiniksa Pharmaceuticals Ltd., as Chief Commercial Officer from 2018 to 2019.
Mr. Kannan received his Masters Business Admin degree from East Carolina University and undergraduate degree from the University of Madras.
Aktive Positionen von Rajkumar Kannan
| Unternehmen | Position | Beginn |
|---|---|---|
| AMRYT PHARMA PLC | Direktor/Vorstandsmitglied | 05.08.2021 |
| I-MAB | Vorstandsvorsitzender | 22.06.2023 |
I-MAB Biopharma Co., Ltd.
 I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Rajkumar Kannan
| Unternehmen | Position | Ende |
|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 21.11.2022 |
| CHIASMA, INC. | Vorstandsvorsitzender | 05.08.2021 |
| KINIKSA PHARMACEUTICALS, LTD. | Corporate Officer/Principal | 01.06.2019 |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Vertrieb & Marketing | 01.06.2014 |
| MERCK KGAA | Corporate Officer/Principal | 01.02.2004 |
Ausbildung von Rajkumar Kannan
| East Carolina University | Masters Business Admin |
| University of Madras | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| MERCK KGAA | Health Technology |
| I-MAB | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Chiasma, Inc.
 Chiasma, Inc. Pharmaceuticals: MajorHealth Technology Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA. | Health Technology |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland. | Health Technology |
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Health Technology |